Q2 FY26: Revenue down 6%, PAT down 36% YoY; new CFO appointed

Revenue DeclineEbitda Margin CompressionRelated Party TransactionsResults View source PDF Explain this filing

EPIGRAL · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-2.3%Reaction day

₹1522.00

prior close

₹1516.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.3%-2.0% vs market

Specialty Chemicals peers, median of 86sector-0.8%-1.5% vs sector

On the reaction day the stock moved 2.0 pts less than Nifty Microcap 250 and 1.5 pts less than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.1

10m

-2.0

15m

-1.5

30m

-4.7

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-2.3-0.3-2.0-0.8-1.5

Next day

+0.5+0.7-0.2+0.3+0.2

-0.3+0.6-0.9-0.2-0.1

-1.3+0.5-1.8-1.0-0.2

-0.7+1.1-1.7-1.0+0.4

-2.6+0.3-2.9-2.0-0.6

-4.4-0.2-4.1-2.9-1.5

15d

-1.8-2.2+0.4-4.9+3.0

-6.4-4.9-1.5-6.4+0.0

-24.3-7.5-16.8-9.6-14.7

-34.0-4.8-29.2-9.4-24.5

UpDownMarket · Nifty Microcap 250Sector · Specialty Chemicals peers, median of 86Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Epigral Q2 FY26 standalone revenue fell 6% YoY to Rs. 587.36 crores from Rs. 626.06 crores. PAT dropped 36% to Rs. 51.52 crores from Rs. 80.53 crores. H1 revenue was Rs. 1,193.90 crores; PAT at Rs. 211.93 crores was higher YoY but includes a one-time deferred tax credit of around Rs. 80.87 crores in Q1 from the lower tax regime switch. Board appointed Mr. Rakesh Agrawal (CA, 29 years experience) as new CFO. Auditor SRBC and Co LLP gave a clean review.

Likely market impact

Revenue decline and weak Q2 profits may weigh on the stock; new CFO appointment is a mild positive.